CompletedNCT03782883
The Impact of Charcot-Marie-Tooth Disease in the Real World
Studying Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vitaccess Ltd
- Principal Investigator
- Mark JW Larkin, PhDVitaccess Ltd
- Enrollment
- 3321 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2023
Study locations (1)
- Vitaccess Ltd, London, United Kingdom
Collaborators
ACMT-Rete per la malattia di Charcot-Marie-Tooth OdV · Charcot-Marie-Tooth Association · Charcot-Marie-Tooth UK · CMT France · Federación Española de Enfermedades Neuromusculares · Hereditary Neuropathy Foundation · Pharnext S.C.A.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03782883 on ClinicalTrials.govOther trials for Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07038239Genotype/Phenotype Correlation of MORC2 MutationsHospices Civils de Lyon
- RECRUITINGNCT06203093Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for IPSC Generation and BiobankingNew York Stem Cell Foundation Research Institute
- RECRUITINGNCT05902351Natural History Study for Charcot Marie Tooth DiseaseHereditary Neuropathy Foundation
See all trials for Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons →